386 related articles for article (PubMed ID: 30900911)
1. Benefits of hepatitis C cure with antivirals: why test and treat?
Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
[TBL] [Abstract][Full Text] [Related]
2. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.
Negro F
Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31636094
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
4. Extrahepatic manifestations of HCV: the role of direct acting antivirals.
Polo ML; Laufer N
Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
6. Managing hepatitis C in patients with the complications of cirrhosis.
Mücke MM; Mücke VT; Lange CM; Zeuzem S
Liver Int; 2018 Feb; 38 Suppl 1():14-20. PubMed ID: 29427491
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
9. Reversion of disease manifestations after HCV eradication.
van der Meer AJ; Berenguer M
J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Implications of Chronic Hepatitis C Virus Infection.
Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
[TBL] [Abstract][Full Text] [Related]
11. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
[TBL] [Abstract][Full Text] [Related]
12. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and Elimination of HCV-Related Liver Disease.
Pradat P; Virlogeux V; Trépo E
Viruses; 2018 Oct; 10(10):. PubMed ID: 30301201
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Virus-Associated Cancers.
Yi Z; Yuan Z
Adv Exp Med Biol; 2017; 1018():129-146. PubMed ID: 29052135
[TBL] [Abstract][Full Text] [Related]
15. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
16. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.
Huang CF; Yu ML
Clin Mol Hepatol; 2020 Jul; 26(3):251-260. PubMed ID: 32188235
[TBL] [Abstract][Full Text] [Related]
17. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
19. The curing regimens of HCV: A SWOT analysis.
Cornberg M; Manns MP
Antivir Ther; 2022; 27(1-2):13596535211072672. PubMed ID: 35491553
[TBL] [Abstract][Full Text] [Related]
20. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
Weisberg IS; Jacobson IM
Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
